Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
JAMA Network Open|September 18, 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialValérie Boige, Hélène Blons, Eric François, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJulien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.
JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohortDavid Tougeron, Frederic Bibeau, Benoist Chibaudel, et al.
The Oncologist|February 12, 2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)Lola-Jade Palmieri, Laurent Mineur, David Tougeron, et al.
Endoscopy|April 12, 2017
Adenoma detection with blue-water infusion colonoscopy: a randomized trialAdriane Lesne, Olivier Rouquette, Sandrine Touzet, et al.
The Oncologist|June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based studyCamille Evrard, Antoine Pelras, Simon Rivet, et al.
Pageof 10